U.S. stock market update: Eli Lilly down 4.86%

U.S. Stock Market Midday Update

Eli Lilly fell 4.86%, with increased trading volume. Based on recent important news:

1. On July 29, Eli Lilly announced that its drug Jaypirca achieved its primary endpoint in the Phase III clinical trial for CLL/SLL, challenging Johnson & Johnson and AbbVie’s Imbruvica. Despite positive data, the market reacted poorly, leading to a 4.86% drop in stock price.

2. On July 29, investors held a bearish outlook on Eli Lilly, with options trading showing significant selling pressure, further exacerbating the decline in stock price.

3. On July 28, the Bank of Montreal raised Eli Lilly's target price to $920, but failed to boost market confidence.

Top Stocks by Industry Trading Volume

Novo Nordisk fell 21.28%, with a significant increase in trading volume. Based on recent important news:

1. On July 29, Novo Nordisk lowered its sales growth forecast for 2025 to 8-14%, primarily due to intensified competition in the U.S. GLP-1 market, resulting in a 21.28% drop in stock price.

2. On July 29, Novo Nordisk appointed a new CEO, and the market expressed doubts about their ability to handle competition and expand the market, leading to further declines in stock price.

3. On July 29, the Chief Financial Officer stated that sales of Ozempic in the U.S. were impacted by competition, leading to a downward revision of performance outlook and putting pressure on the stock price.

Merck fell 2.28%, with increased trading volume. Based on recent important news:

1. On July 29, Merck announced its second-quarter financial report, with net profit down 20.3% year-on-year. The stock price initially fell by 8.8%, but the decline narrowed to 3.3%.

2. On July 29, Merck announced a $3 billion cost-cutting plan to address competition from Keytruda generics, leading to a sharp decline in stock price.

3. On July 29, the full-year sales forecast was lowered to $64.3 billion to $65.3 billion, with a negative market reaction.

AstraZeneca rose 3.17%, with increased trading volume. Based on recent important news:

1. On July 29, AstraZeneca announced its second-quarter financial report, with profits exceeding expectations due to strong sales of cancer drugs, resulting in a 3.17% increase in stock price.

2. On July 29, AstraZeneca announced a $50 billion investment in the U.S. to expand production and R&D capabilities, boosting market confidence.

3. On July 29, AstraZeneca maintained its full-year performance forecast, demonstrating confidence in future development and driving up stock price.

Top Stocks by Industry Market Capitalization

Johnson & Johnson rose 0.91%, with a market capitalization of $403.9 billion. Based on recent important news:

1. On July 29, Johnson & Johnson submitted a supplemental biologics license application, adding new evidence for TREMFYA in psoriatic arthritis, which boosted stock price.

2. On July 29, Johnson & Johnson launched the VirtuGuide™ AI system to streamline bunion surgery, enhancing market confidence

3. On July 28, analysts raised Johnson & Johnson's target price to $165, reflecting optimistic market expectations